Human α-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: Vector diffusion and biodistribution

Human Gene Therapy

Volumn 20, Issue 4, 2009, Pages 350-360

  Ciron, Carine ^a   Cressant, Arnaud ^b   Roux, Françoise ^c   Raoul, Sylvie ^d   Cherel, Yan ^e   Hantraye, Philippe ^f,g   Déglon, Nicole ^f,g   Schwartz, Bertrand ^a   Barkats, Martine ^h   Heard, Jean Michel ^b   Tardieu, Marc ⁱ   Moullier, Philippe ^a,j,k   Colle, Marie Anne ^e  

^a INSERM   (France)

^b INSTITUT PASTEUR   (France)

^c LUNAM UNIVERSITÉ   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e INRA UMR 703   (France)

^f INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^g CNRS   (France)

^h GÉNÉTHON   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j ETABLISSEMENT FRANÇAIS DU SANG   (France)

^k UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; LEVO IDURONIDASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 1; ADENO ASSOCIATED VIRUS TYPE 2; ADENO ASSOCIATED VIRUS TYPE 5; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAPSULA INTERNA; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; FOLLOW UP; GENE TRANSFER; HUMAN; HURLER SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; MACACA; MALE; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NERVE; POLYMERASE CHAIN REACTION; PUTAMEN; SOUTHERN BLOTTING; SPINAL CORD; VIRAL GENE DELIVERY SYSTEM; VIRUS NEUTRALIZATION;

ANIMALS; BRAIN; CRANIAL NERVES; DEPENDOVIRUS; DIFFUSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HUMANS; IDURONIDASE; INJECTIONS, INTRAVENTRICULAR; INTERNAL CAPSULE; LEUKOCYTES, MONONUCLEAR; MACACA; ORGAN SPECIFICITY; PERIPHERAL NERVES; PUTAMEN; SPINAL CORD; TISSUE DISTRIBUTION; TRANSGENES; VIRION;

ADENO-ASSOCIATED VIRUS; CANIS FAMILIARIS; MACACA; PRIMATES;

EID: 64049083111     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.155     Document Type: Article

References (45)

1. Bankiewicz, K.S., Forsayeth, J., Eberling, J.L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R.E., Eckelman, W., Reutter, B., and Cunningham, J. (2006). Longterm clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14, 564-570.
2. Bosch, A., Perret, E., Desmaris, N., Trono, D., and Heard, J.M. (2000). Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11, 1139-1150.
3. Brockstedt, D.G., Podsakoff, G.M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., and Engleman, E.G. (1999). Induction of immunity to antigens expressed by recombinant adenoassociated virus depends on the route of administration. Clin. Immunol. 92, 67-75.
4. Burger, C., Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., Williams, P., Zolotukhin, S., Reier, P.J., Mandel, R.J., and Muzyczka, N. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display 358 differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10, 302-317.
5. Burger, C., Nash, K., and Mandel, R.J. (2005). Recombinant adeno-associated viral vectors in the nervous system. Hum. Gene Ther. 16, 781-791.
6. Cearley, C.N., and Wolfe, J.H. (2007). A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27, 9928-9940.
7. Chenuaud, P., Larcher, T., Rabinowitz, J.E., Provost, N., Cherel, Y., Casadevall, N., Samulski, R.J., and Moullier, P. (2004). Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103, 3303-3304.
8. Ciron, C., Desmaris, N., Colle, M.A., Raoul, S., Joussemet, B., Verot, L., Ausseil, J., Froissart, R., Roux, F., Cherel, Y., Ferry, N., Lajat, Y., Schwartz, B., Vanier, M.T., Maire, I., Tardieu, M., Moullier, P., and Heard, J.M. (2006). Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol. 60, 204-213.
9. Cressant, A., Desmaris, N., Verot, L., Brejot, T., Froissart, R., Vanier, M.T., Maire, I., and Heard, J.M. (2004). Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci. 24, 10229-10239.
10. Crystal, R.G., Sondhi, D., Hackett, N.R., Kaminsky, S.M., Worgall, S., Stieg, P., Souweidane, M., Hosain, S., Heier, L., Ballon, D., Dinner, M., Wisniewski, K., Kaplitt, M., Greenwald, B.M., Howell, J.D., Strybing, K., Dyke, J., and Voss, H. (2004). Clinical protocol: Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. 15, 1131-1154.
11. Davidson, B.L., Stein, C.S., Heth, J.A., Martins, I., Kotin, R.M., Derksen, T.A., Zabner, J., Ghodsi, A., and Chiorini, J.A. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U.S.A. 97, 3428-3432.
12. Desmaris, N., Verot, L., Puech, J.P., Caillaud, C., Vanier, M.T., and Heard, J.M. (2004). Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 56, 68-76.
13. Favre, D., Provost, N., Blouin, V., Blancho, G., Cherel, Y., Salvetti, A., and Moullier, P. (2001). Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol. Ther. 4, 559-566.
14. Flotte, T.R., Conlon, T.J., Poirier, A., Campbell-Thompson, M., and Byrne, B.J. (2007). Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites. Hum. Gene Ther. 18, 245-256.
15. Gao, G., Lebherz, C., Weiner, D.J., Grant, R., Calcedo, R., McCullough, B., Bagg, A., Zhang, Y., and Wilson, J.M. (2004). Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103, 3300-3302.
16. Grimm, D., Kay, M.A., and Kleinschmidt, J.A. (2003). Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7, 839-850.
17. Hadaczek, P., Kohutnicka, M., Krauze, M.T., Bringas, J., Pivirotto, P., Cunningham, J., and Bankiewicz, K. (2006). Convectionenhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 17, 291-302.
18. Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I.H., Mao, Q., Yang, L., Kotin, R.M., Paulson, H.L., and Davidson, B.L. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U.S.A. 102, 5820-5825.
19. Herzog, R.W., Fields, P.A., Arruda, V.R., Brubaker, J.O., Armstrong, E., McClintock, D., Bellinger, D.A., Couto, L.B., Nichols, T.C., and High, K.A. (2002). Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum. Gene Ther. 13, 1281-1291.
20. Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.J., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G., Sharrar, W., Liouterman, L., Camp, A., Kolodny, E., Samulski, J., and Leone, P. (2002). Clinical protocol: Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 13, 1391-1412.
21. Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., Young, D., Strybing, K., Eidelberg, D., and During, M.J. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369, 2097-2105.
22. Klein, R.L., Dayton, R.D., Tatom, J.B., Henderson, K.M., and Henning, P.P. (2008). AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: Effects of serotype, promoter and purification method. Mol. Ther. 16, 89-96.
23. Liu, G., Martins, I., Wemmie, J.A., Chiorini, J.A., and Davidson, B.L. (2005). Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. 25, 9321-9327.
24. Mandel, R.J., and Burger, C. (2004). Clinical trials in neurological disorders using AAV vectors: Promises and challenges. Curr. Opin. Mol. Ther. 6, 482-490.
25. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P.K., Nakai, H., Chew, A., Leonard, D., Wright, J.F., Lessard, R.R., Sommer, J.M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H.C., High, K.A., and Kay, M.A. (2006). Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347.
26. Mastakov, M.Y., Baer, K., Xu, R., Fitzsimons, H., and During, M.J. (2001). Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol. Ther. 3, 225-232.
27. McCown, T.J. (2005). Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 5, 333-338.
28. McPhee, S.W., Janson, C.G., LI, C., Samulski, R.J., Camp, A.S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., and Leone, P. (2006). Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8, 577-588.
29. Nguyen, J.B., Sanchez-Pernaute, R., Cunningham, J., and Bankiewicz, K.S. (2001). Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12, 1961-1964.
30. Provost, N., Le Meur, G., Weber, M., Mendes-Madeira, A., Podevin, G., Cherel, Y., Colle, M.A., Deschamps, J.Y., Moullier, P., and Rolling, F. (2005). Biodistribution of rAAV vectors following intraocular administration: Evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther. 11, 275-283.
31. Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791-801.
32. Salvetti, A., Oreve, S., Chadeuf, G., Favre, D., Cherel, Y., Champion-Arnaud, P., David-Ameline, J., and Moullier, P. (1998). Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9, 695-706.
33. Sevin, C., Benraiss, A., van Dam, D., Bonnin, D., Nagels, G., Verot, L., Laurendeau, I., Vidaud, M., Gieselmann, V., Vanier, M., De Deyn, P.P., Aubourg, P., and Cartier, N. (2006). Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum. Mol. Genet 15, 53-64.
34. Skorupa, A.F., Fisher, K.J., Wilson, J.M., Parente, M.K., and Wolfe, J.H. (1999). Sustained production of β-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp. Neurol. 160, 17-27.
35. Sondhi, D., Peterson, D.A., Giannaris, E.L., Sanders, C.T., Mendez, B.S., De, B., Rostkowski, A.B., Blanchard, B., Bjugstad, K., Sladek, J.R., Jr., Redmond, D.E., Jr., Leopold, P.L., Kaminsky, S.M., Hackett, N.R., and Crystal, R.G. (2005). AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther. 12, 1618-1632.
36. Sondhi, D., Hackett, N.R., Peterson, D.A., Stratton, J., Baad, M., Travis, K.M., Wilson, J.M., and Crystal, R.G. (2007). Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther. 15, 481-491.
37. Taymans, J.M., Vandenberghe, L.H., Haute, C.V., Thiry, I., Deroose, C.M., Mortelmans, L., Wilson, J.M., Debyser, Z., and Baekelandt, V. (2007). Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 18, 195-206.
38. Toromanoff, A., Cherel, Y., Guilbaud, M., Penaud-Budloo, M., Snyder, R.O., Haskins, M.E., Deschamps, J.Y., Guigand, L., Podevin, G., Arruda, V.R., High, K.A., Stedman, H.H., Rolling, F., Anegon, I., Moullier, P., and Le Guiner, C. (2008). Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol. Ther. 16, 1291-1299.
39. Vandenberghe, L.H., and Wilson, J.M. (2007). AAV as an immunogen. Curr. Gene Ther. 7, 325-333.
40. Vite, C.H., Passini, M.A., Haskins, M.E., and Wolfe, J.H. (2003). Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. 10, 1874-1881.
41. Vite, C.H., McGowan, J.C., Niogi, S.N., Passini, M.A., Drobatz, K.J., Haskins, M.E., and Wolfe, J.H. (2005). Effective gene therapy for an inherited CNS disease in a large animal model. Ann. Neurol. 57, 355-364.
42. Weber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Cherel, Y., Chenuaud, P., Samulski, J., Moullier, P., and Rolling, F. (2003). Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol. Ther. 7, 774-781.
43. Wu, P., Phillips, M.I., Bui, J., and Terwilliger, E.F. (1998). Adenoassociated virus vector-mediated transgene integration into neurons and other nondividing cell targets. J. Virol. 72, 5919-5926.
44. Xiao, X., Li, J., McCown, T.J., and Samulski, R.J. (1997). Gene transfer by adeno-associated virus vectors into the central nervous system. Exp. Neurol. 144, 113-124.
45. Xu, Y., Gu, Y., Wu, P., Li, G.W., and Huang, L.Y. (2003). Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum. Gene Ther. 14, 897-906.